Plant Name: Lepidosperma ustulatum
Taxonomic Information:
Plant ID: NPO4910
Plant Latin Name: Lepidosperma ustulatum
Taxonomy Genus: Lepidosperma
Taxonomy Family: Cyperaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
310184-1
Used in Medicines:
Unknown.
Geographical Distribution:
Australia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| BLM; ALOX12; HSD17B2; HSD17B10; NOX4; AOX1; POLB; | |
| AURKB; PIM1; MET; FLT3; CDK1; EGFR; AXL; KDR; IGF1R; | |
| CA2; CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| TYR; | |
| MMP12; | |
| AHR; HIF1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.667E-09 | 4.551E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.077E-08 | 1.804E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.444E-08 | 2.096E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.687E-08 | 4.437E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.264E-07 | 1.692E-04 | ALOX12, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.527E-07 | 2.191E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.530E-07 | 2.562E-04 | AHR, ESR1, ESR2, ESRRA, ESRRB, PIM1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.628E-07 | 3.316E-04 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, MMP12 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.033E-06 | 3.749E-04 | CA12, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.054E-06 | 3.763E-04 | AHR, AXL, EGFR, ESR1, ESR2, ESRRA, ESRRB, FLT3, IGF1R, KDR, MET, NPSR1, TSHR |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.173E-06 | 6.530E-04 | BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.818E-06 | 7.968E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.007E-06 | 8.395E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.099E-06 | 1.026E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, ESR1, HSD17B2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 5.565E-06 | 1.317E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 7.302E-06 | 1.595E-03 | AURKB, BLM, EGFR, HIF1A, NOX4, POLB, TYR |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 8.393E-06 | 1.810E-03 | CDK1, ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.614E-06 | 1.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.614E-06 | 1.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.012E-06 | 1.869E-03 | CA2, CA7 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.382E-06 | 1.927E-03 | AXL, CDK1, EGFR, FLT3 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 9.873E-06 | 1.991E-03 | ALOX12, EGFR, HIF1A, IGF1R, KDR, MET, NOX4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.534E-05 | 2.760E-03 | ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.800E-05 | 2.993E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.800E-05 | 2.993E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.800E-05 | 2.993E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.387E-05 | 3.821E-03 | AHR, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 2.872E-05 | 4.408E-03 | CDK1, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.491E-05 | 6.392E-03 | CYP1A2, CYP2C9 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.911E-05 | 6.769E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.982E-05 | 6.823E-03 | AXL, FLT3, HIF1A, POLB |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 5.860E-05 | 7.781E-03 | AXL, HIF1A, MMP12 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 6.281E-05 | 8.189E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 6.281E-05 | 8.189E-03 | FLT3, KDR |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 6.281E-05 | 8.189E-03 | EGFR, ESR1 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 6.463E-05 | 8.377E-03 | CYP1A2, EGFR, ESR1, ESRRA |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.663E-05 | 9.534E-03 | EGFR, IGF1R, KDR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.768E-05 | 9.610E-03 | ESR1, ESR2, ESRRA, ESRRB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.090E-07 | 2.832E-05 | CYP1A2, CYP1A1, AOX1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.630E-08 | 1.516E-06 | CA12, CA2, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.078E-06 | 3.341E-05 | KDR, HIF1A, ESR1, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.516E-06 | 3.526E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.767E-06 | 5.146E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.378E-06 | 6.570E-05 | CYP2C9, CYP1A2, CYP1A1, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.945E-06 | 6.570E-05 | FLT3, MET, HIF1A, EGFR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.972E-06 | 8.105E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.108E-05 | 1.145E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.371E-04 | 2.004E-03 | MET, EGFR, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.178E-04 | 2.004E-03 | CYP2C9, CYP1A2, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.204E-04 | 3.226E-03 | FLT3, HIF1A, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.695E-04 | 2.643E-03 | KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.357E-04 | 2.894E-03 | KDR, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.679E-04 | 2.076E-03 | MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.737E-04 | 3.335E-03 | KDR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.298E-04 | 3.445E-03 | ESR1, EGFR, ESR2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 9.048E-04 | 4.157E-03 | CYP2C9, HSD17B2, CYP1A2, CYP1A1, AOX1, ALOX12, TYR, HSD17B10 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 9.388E-04 | 4.157E-03 | KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.068E-04 | 3.460E-03 | HIF1A, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.022E-03 | 4.320E-03 | FLT3, KDR, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.556E-03 | 5.994E-03 | PIM1, CYP1B1, MET, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.572E-03 | 9.198E-03 | KDR, MET, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 1.611E-03 | 5.994E-03 | AOX1, TYR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 6.940E-04 | 3.460E-03 | CA2, CA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.107E-03 | 4.474E-03 | CYP2C9, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; FLT3; HIF1A; EGFR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; TYR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
